

PRODUCT INFORMATION




XL888

Item No. 16309

CAS Registry No.: 1149705-71-4
Formal Name: N¹-[(3-endo)-8-[5-(cyclopropylcarbonyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-5-[[[(1R)-1-methylpropyl]amino]-1,4-benzenedicarboxamide

MF: C₂₉H₃₇N₅O₃
FW: 503.6
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

XL888 is supplied as a crystalline solid. A stock solution may be made by dissolving the XL888 in the solvent of choice, which should be purged with an inert gas. XL888 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of XL888 in these solvents is approximately 30 mg/ml.

XL888 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, XL888 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. XL888 has a solubility of approximately 0.1 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Heat shock protein 90 (Hsp90) is a chaperone that maintains the functionality of client proteins involved in cell proliferation, cell cycling, and apoptosis.¹ XL888 is an ATP-competitive inhibitor of Hsp90.² Through this action, specific client proteins are degraded, resulting in cell cycle arrest or apoptosis.³⁻⁵ XL888 is orally bioavailable and shows efficacy in tumor regression in gastric carcinoma and melanoma xenografts in mice.^{2,4}

References

1. Taldone, T., Sun, W., and Chiosis, G. Discovery and development of heat shock protein 90 inhibitors. *Bioorg. Med. Chem.* **17**(6), 2225-2235 (2009).
2. Bussenius, J., Blazey, C.M., Aay, N., *et al.* Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90. *Bioorg. Med. Chem. Lett.* **22**(17), 5396-5404 (2012).
3. Lyman, S.K., Crawley, S.C., Gong, R., *et al.* High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. *PLoS One* **6**(3), 1-14 (2011).
4. Haarberg, H.E., Paraiso, K.H.T., Wood, E., *et al.* Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an *in vivo* model of NRAS-mutant melanoma. *Mol. Cancer Ther.* **12**(6), 901-912 (2013).
5. Paraiso, K.H.T., Haarberg, H.E., Wood, E., *et al.* The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. *Clin. Cancer Res.* **18**(9), 2502-2514 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM